Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IMMPNASDAQ:SLDBNASDAQ:SLRNNYSEAMERICAN:XTNT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIMMPImmutep$1.51+1.3%$1.78$1.32▼$3.34$219.79M1.94193,834 shs33,078 shsSLDBSolid Biosciences$2.70-0.4%$4.37$2.48▼$10.99$209.23M2.07888,681 shs1.29 million shsSLRNAcelyrin$2.23+2.3%$2.44$1.85▼$7.25$225.02M1.121.22 million shs603,326 shsXTNTXtant Medical$0.39-2.5%$0.50$0.33▼$0.97$54.21M0.3593,328 shs62,446 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIMMPImmutep+1.34%+4.14%-15.17%-21.35%-34.63%SLDBSolid Biosciences-0.37%+1.12%-46.95%-14.01%-73.00%SLRNAcelyrin+2.29%+7.21%-18.91%+10.40%-59.60%XTNTXtant Medical-2.50%+2.28%-18.75%-26.36%-53.42%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIMMPImmutep1.6284 of 5 stars3.52.00.00.03.30.00.0SLDBSolid Biosciences3.39 of 5 stars3.72.00.00.03.04.21.3SLRNAcelyrin3.5858 of 5 stars3.25.00.00.03.13.31.3XTNTXtant Medical2.0635 of 5 stars3.54.00.00.01.31.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIMMPImmutep 3.00Buy$8.50462.91% UpsideSLDBSolid Biosciences 3.33Buy$15.67480.25% UpsideSLRNAcelyrin 2.40Hold$9.60330.49% UpsideXTNTXtant Medical 3.00Buy$2.25476.92% UpsideCurrent Analyst Ratings BreakdownLatest XTNT, SLRN, IMMP, and SLDB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/13/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$12.00 ➝ $11.003/10/2025SLDBSolid BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$16.00 ➝ $20.003/7/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.002/19/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$15.00 ➝ $16.00(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIMMPImmutep$5.14M42.76N/AN/A$1.05 per share1.44SLDBSolid Biosciences$8.09M25.86N/AN/A$6.27 per share0.43SLRNAcelyrinN/AN/AN/AN/A$6.74 per shareN/AXTNTXtant Medical$91.30M0.59$0.02 per share20.06$0.39 per share1.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIMMPImmutep-$28.01MN/A0.00N/AN/AN/AN/AN/AN/ASLDBSolid Biosciences-$96.01M-$3.04N/AN/AN/AN/A-58.75%-47.84%5/13/2025 (Estimated)SLRNAcelyrin-$381.64M-$2.50N/AN/AN/AN/A-44.12%-39.02%5/13/2025 (Estimated)XTNTXtant Medical$660K-$0.13N/A∞N/A-15.45%-37.07%-18.47%5/13/2025 (Estimated)Latest XTNT, SLRN, IMMP, and SLDB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SLRNAcelyrin-$0.95N/AN/AN/AN/AN/A5/13/2025Q1 2025XTNTXtant Medical-$0.02N/AN/AN/A$30.65 millionN/A3/19/2025Q4 2024SLRNAcelyrin-$0.86-$0.79+$0.07-$0.79N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIMMPImmutepN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ASLRNAcelyrinN/AN/AN/AN/AN/AXTNTXtant MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIMMPImmutep0.0118.2518.25SLDBSolid BiosciencesN/A7.857.85SLRNAcelyrinN/A7.157.15XTNTXtant Medical0.422.120.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIMMPImmutep2.32%SLDBSolid Biosciences81.46%SLRNAcelyrin87.31%XTNTXtant Medical69.33%Insider OwnershipCompanyInsider OwnershipIMMPImmutep3.07%SLDBSolid Biosciences13.63%SLRNAcelyrin13.60%XTNTXtant Medical9.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIMMPImmutep2,021145.56 million141.09 millionOptionableSLDBSolid Biosciences10077.49 million35.05 millionOptionableSLRNAcelyrin135100.91 million86.68 millionOptionableXTNTXtant Medical120139.01 million125.52 millionNot OptionableXTNT, SLRN, IMMP, and SLDB HeadlinesRecent News About These CompaniesWhy Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Down 14.76%April 10, 2025 | aaii.comXtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above 200 Day Moving Average - Here's What HappenedApril 10, 2025 | marketbeat.comXtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Significant Drop in Short InterestMarch 31, 2025 | marketbeat.comXtant Medical (NYSEAMERICAN:XTNT) Shares Cross Above Two Hundred Day Moving Average - Time to Sell?March 22, 2025 | marketbeat.comWhy Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Up 12.52%March 22, 2025 | aaii.comXtant Medical price target lowered to $2 from $3 at BTIGMarch 8, 2025 | markets.businessinsider.comXtant Medical Holdings, Inc. (AMEX:XTNT) Q4 2024 Earnings Call TranscriptMarch 8, 2025 | msn.comXtant Medical Holdings, Inc.: Xtant Medical Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 7, 2025 | finanznachrichten.deXtant Medical Holdings, Inc. (XTNT) Q4 2024 Earnings Call TranscriptMarch 6, 2025 | seekingalpha.comXtant Medical Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 6, 2025 | accessnewswire.comAnalysts Offer Insights on Healthcare Companies: Xtant Medical Holdings (XTNT) and LifeMD (LFMD)March 6, 2025 | markets.businessinsider.comXtant Medical to Issue Fourth Quarter and Year End 2024 Financial Results on March 6, 2025February 28, 2025 | accessnewswire.comWhy Xtant Medical Holdings, Inc.’s (XTNT) Stock Is Up 15.50%February 1, 2025 | aaii.comEarnings call: Xtant Medical announces revenue growth in Q3 2024November 15, 2024 | uk.investing.comXtant Medical Reports Q3 2024 Revenue Growth and New Product LaunchesNovember 13, 2024 | markets.businessinsider.comXtant Medical Holdings, Inc.: Xtant Medical Reports Third Quarter 2024 Financial ResultsNovember 13, 2024 | finanznachrichten.deXtant Medical Holdings, Inc. (XTNT) Q3 2024 Earnings Conference Call TranscriptNovember 12, 2024 | seekingalpha.comXtant Medical Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | accesswire.comXtant Medical Hldgs's Earnings OutlookNovember 12, 2024 | benzinga.comXtant Medical Holdings, Inc.: Xtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select ConferenceNovember 12, 2024 | finanznachrichten.deXtant Medical to Attend the 15th Annual Craig-Hallum Alpha Select ConferenceNovember 11, 2024 | accesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound PotentialCan Solid Biosciences Challenge Sarepta in the DMD Market?By Leo Miller | April 8, 2025View Can Solid Biosciences Challenge Sarepta in the DMD Market?XTNT, SLRN, IMMP, and SLDB Company DescriptionsImmutep NASDAQ:IMMP$1.51 +0.02 (+1.34%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.50 -0.01 (-0.66%) As of 04/15/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immutep Limited, a clinical-stage biotechnology company, engages in developing novel LAG-3 Immunotherapy for cancer and autoimmune diseases. The company is involved in advancing therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), a cell surface molecule that plays a vital role in regulating the immune system. Its LAG-3 immunotherapies are designed to harness and strengthen the power of patients' immune systems to fight cancer and autoimmune disease. Its lead product candidate is eftilagimod alpha (efti or IMP321) for the treatment of different types of cancers. The trials that efi is being evaluated in include TACTI-002, a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC); TACTI-003, a Phase IIb clinical trial to treat HNSCC; and INSIGHT-003, a Phase I clinical trial for the treatment of NSCLC, as well as INSIGHT-005, a Phase I/IIa clinical trial to treat solid tumors. In addition, it offers IMP761, an agonist of lymphocyte activation gene 3 for autoimmune disease; IMP701, an antagonist antibody that acts to stimulate T cell proliferation in cancer patients; and IMP731, a depleting antibody that removes T cells involved in autoimmunity. The company has collaboration agreements with GlaxoSmithKline, Novartis, CYTLIMIC Inc., Merck & Co., Inc., Institute of Clinical Cancer Research, Merck KGaA, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is headquartered in Sydney, Australia.Solid Biosciences NASDAQ:SLDB$2.70 -0.01 (-0.37%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$2.68 -0.02 (-0.74%) As of 04/15/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.Acelyrin NASDAQ:SLRN$2.23 +0.05 (+2.29%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$2.22 0.00 (-0.22%) As of 04/15/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis. It is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody which is in Phase 1 clinical trials for use in the treatment of thyroid eye disease. In addition, the company's develops SLRN-517, a fully human IgG1 monoclonal antibody targeting c-KIT, which is in preclinical stage for use in the treatment of chronic urticaria. Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.Xtant Medical NYSEAMERICAN:XTNT$0.39 -0.01 (-2.50%) Closing price 04/15/2025 04:10 PM EasternExtended Trading$0.40 +0.01 (+1.79%) As of 04/15/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, it offers Certex spinal fixation, Spider cervical plating, Streamline OCT, CervAlign, Axle interspinous fusion, Xpress minimally invasive pedicle screw, Fortex pedicle screw, Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation systems, and Silex sacroiliac joint fusion systems. Further, it provides Calix for cervical and thoracolumbar applications, as well as Irix-C Cervical Integrated Fusion, Irix-A Lumbar Integrated Fusion, Fortilink, and Irix-A Lumbar integrated fusion systems; Coflex device for lumbar spinal stenosis; and CoFix implant for back and disc pain. The company is headquartered in Belgrade, Montana. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Congress! Who Traded What During the Tariff-Induced Meltdown Beware of BigBear.ai: Insiders Are Selling—Should You? NATO Deal Sparks 4% Jump in Palantir Stock—What’s Next? Microsoft: A Blend of Growth and Value Amid Tariff Concerns Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold Don’t Fear, New Highs for Fastenal Will Soon Be Here Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
